...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.
【24h】

Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.

机译：左西替利嗪5 mg和地氯雷他定5 mg在慢性特发性荨麻疹患者中的疗效比较。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Nonsedating H(1)-antihistamines are recommended for the treatment of urticaria by the recent EAACI/GA(2)LEN/EDF guidelines. The aim of this study was to compare the efficacy, after 4 weeks of treatment, with levocetirizine 5 mg and desloratadine 5 mg, both once daily in the morning, in symptomatic chronic idiopathic urticaria (CIU) patients. METHODS: This multi-center, randomized, double-blind study involved 886 patients (438 on levocetirizine and 448 on desloratadine). The primary objective was to compare their efficacy on the mean pruritus severity score after 1 week of treatment. Mean pruritus severity score over 4 weeks and pruritus duration score, number and size of wheals, mean CIU composite score (sum of the scores for pruritus severity and numbers of wheals), quality of life, and the patient's and investigator's global satisfaction with treatment, were secondary efficacy measures. RESULTS: Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadineover the first treatment week; mean pruritus severity scores of 1.02 and 1.18 for levocetirizine and desloratadine, respectively (P < 0.001). The result was similar for the entire 4-week treatment period (P = 0.004). In addition, levocetirizine decreased pruritus duration and the mean CIU composite scores to a significantly greater extent than desloratadine during the first week (P = 0.002 and 0.005, respectively) and over the entire study (P = 0.009 and P < 0.05, respectively). Similarly, levocetirizine increased the patients' global satisfaction after one and 4 weeks (P = 0.012 and 0.021, respectively), compared with desloratadine. Safety and tolerability were similar in both groups. CONCLUSIONS: Levocetirizine 5 mg was significantly more efficacious than desloratadine 5 mg in the treatment of CIU symptoms.
机译：背景：最新的EAACI / GA（2）LEN / EDF指南推荐使用非镇静性H（1）-抗组胺药治疗荨麻疹。这项研究的目的是比较治疗4周后每天两次使用有左西替利嗪5 mg和去氯雷他定5 mg对有症状的慢性特发性荨麻疹（CIU）患者的疗效。方法：这项多中心，随机，双盲研究涉及886名患者（左西替利嗪438名，去氯雷他定448名）。主要目的是比较治疗1周后它们对平均瘙痒严重程度评分的疗效。超过4周的平均瘙痒严重程度评分和瘙痒持续时间评分，风团数量和大小，平均CIU综合评分（瘙痒严重程度和风团数量得分总和），生活质量以及患者和研究者对治疗的总体满意度，是次要的疗效指标。结果：在治疗的第一周，左西替利嗪导致的瘙痒严重程度的降低明显大于地氯雷他定。左西替利嗪和去氯雷他定的瘙痒严重程度平均评分分别为1.02和1.18（P <0.001）。在整个4周的治疗期间，结果相似（P = 0.004）。此外，左西替利嗪在第一周（分别为P = 0.002和0.005）和整个研究期间（分别为P = 0.009和P <0.05），缩短了瘙痒持续时间，并且平均CIU综合评分明显高于地氯雷他定。同样，与地氯雷他定相比，左西替利嗪在1周和4周后可提高患者的总体满意度（分别为P = 0.012和0.021）。两组的安全性和耐受性相似。结论：5 mg左西替利嗪在治疗CIU症状方面比地氯雷他定5 mg更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号